JWH 015 is a cannabinoid receptor 2 (CB2) agonist, with some cannabinoid receptor 1 activity. Some examples of beneficial effects found for JWH 015 include antinociceptive properties in a CFA inflammatory pain mouse model. Additionally, JWH 015 shows anti-obesity effects in mice by reducing the size of adipose tissue cells.
| Cas No. | 155471-08-2 |
|---|---|
| Purity | ≥98% |
| Formula | C23H21NO |
| Formula Wt. | 327.43 |
| Chemical Name | (2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone |
| IUPAC Name | (2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone |
| Solubility | Soluble to 10 mM in DMSO and to 25 mM in ethanol |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Verty AN, Stefanidis A, McAinch AJ et al. Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice. PLoS One. 2015 Nov 20;10(11):e0140592. PMID: 26588700.
Murataeva N, Mackie K, and Staiker A. The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons. Pharmacol Res. 2012 Nov;66(5):437-42. PMID: 22921769.
Negrete R, Hervera A, Leazez S et al. The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids. PLoS One. 2011;6(10):e26688. PMID: 22031841.
